SOLICITATION NOTICE
A -- Recruit Breast Cancer Patients and Collect Clinical and Epidemiological Data and Biospecimens - Statement of Work
- Notice Date
- 8/13/2013
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions-Treatment and Support Branch, Bldg 244, Room 112, Frederick, Maryland, 21702
- ZIP Code
- 21702
- Solicitation Number
- N01CP34405-11
- Archive Date
- 9/12/2013
- Point of Contact
- Brenda Oberholzer, Phone: 301-624-8750, Brian Madgey, Phone: 301 624-8760
- E-Mail Address
-
oberholzerb@mail.nih.gov, brian.madgey@nih.gov
(oberholzerb@mail.nih.gov, brian.madgey@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- SOW Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, Riverside Five, Suite 400, Room 4025, 8490 Progress Drive, Frederick, MD 21701, UNITED STATES Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG), is anticipating to award a Firm-Fixed Price non-competitive purchase order to The Chinese University of Hong Kong, in Hong Kong SAR, China to provide recruitment of patients, collection of samples, and the related epidemiologic data from Asian populations. The services herein are being procured in accordance with the simplified acquisition procedures as authorized by FAR Part 13.106-1 (b)(1). The North American Industry Classification System code is 541711 and the business size standard is 500 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance shall be for twelve (12) months from date of award. Previous molecular classification studies in Asian breast cancer are limited and have generated inconsistent data. Results from some studies suggest that Asian women were more likely to develop TN tumors compared with white women (32). In contrast, data based on the California Cancer Registry suggested that Asian women had lower risk of developing TN tumors but higher risk of HER2-overexpressing tumors (33-35). In addition to the inconsistency, it is unclear or is simply due to lower incidence of ER+ tumors. Tumor stratification in previously conducted studies was mostly based on clinical markers only (eg. ER, PR, and HER2), and used varying criteria to define positivity and little or no quantitation. A more refined molecular classification approach is needed to achieve more accurate tumor stratification and to identify etiologic factors underlying specific tumor subtypes, which will help distinguish the interrelated effects of age and race in breast cancer. In addition, Asian breast cancer shows great heterogeneity by population/ethnicity, geographic region, and level of economic development. Incidence rates and tumor characteristics vary even within the same geographic areas. Differences in both genetic and environmental risk factors may contribute to the variations, and studying a variety of Asian populations will improve our understanding of the etiologic heterogeneity of breast cancer. Therefore we propose to conduct a molecular epidemiology study by collecting normal and breast tumor tissues from breast cancer cases who are enrolled in an ongoing breast cancer case-control study (Night shift and breast cancer: a case-control study among Hong Kong women) led by Dr. Shelly Tse at Chinese University in Hong Kong (CUHK). Eligible cases in the nightshift and breast cancer case-control study are identified from the Surgery or Oncology Departments of hospitals in three clusters in Hong Kong. Each case is frequency-matched in five-year age groups to a hospital control who is randomly selected from the same hospital where the case comes from. All cases and controls are Chinese females, and all controls have no history of a physician-diagnosed cancer at any site. Approximately 1,000 incident female breast cancer cases and 1,000 age-matched controls are expected to be recruited into the case-control study by the end of year 2013. Questionnaire data (including basic socio-demographic characteristics, lifetime habits of smoking and alcohol drinking, dietary habits and intake of supplements, anthropometric risk factors, reproductive factors, history of benign breast diseases, family cancer history of breast cancer, occupational and recreational physical activity, etc) and blood are being collected from each participating subject. The Chinese University of Hong Kong is uniquely qualified to provide this service as it already a current study underway from which Asian patients can be recruited for the samples and data needed for this project. This notice is not a request for competitive quotation. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Capability statements must be received in the contracting office by 12:00 PM EST, on August 28, 2013. For further information, please contact Brenda Oberholzer, Contracting Officer via electronic mail at oberholzerb@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. No faxed or emailed capability statements will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA) thru sam.gov. Reference: NCI-34405-11on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/FCRF2/N01CP34405-11/listing.html)
- Record
- SN03147122-W 20130815/130813235633-0660a9c0ce45626a7ec9d40acf4aa754 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |